Nanexa AB (publ) announced that the first dose of NEX-20 has been administrated in the Phase 1 study NEX-20-01. NEX-20-01 is a phase 1 study dosing a single injection of NEX-20 to healthy volunteers to follow the pharmacokinetic profile, safety, and tolerability. The study is designed to study different dose levels in sequential dose groups, based on data evaluated during the course of the study.

NEX-20 is a long-acting formulation of lenalidomide based on Nanexa's drug delivery system PharmaShell®. Lenalidomide is an immunomodulatory compound targeting both cancer cells and their microenvironment (1). Currently patients take lenalidomide daily as an oral capsule for 21-28 days in 28-day cycles.